Remyelination in humans due to a retinoid‐X receptor agonist is age‐dependent

Remyelination efficiency declines with advancing age in animal models, but this has been harder to demonstrate in people with multiple sclerosis. We show that bexarotene, a putatively remyelinating retinoid‐X receptor agonist, shortened the visual evoked potential latency in patients with chronic op...

Full description

Saved in:
Bibliographic Details
Published in:Annals of clinical and translational neurology Vol. 9; no. 7; pp. 1090 - 1094
Main Authors: McMurran, Christopher E., Mukherjee, Trisha, Brown, J William L., Michell, Andrew W., Chard, Declan T., Franklin, Robin J. M., Coles, Alasdair J., Cunniffe, Nick G.
Format: Journal Article
Language:English
Published: United States John Wiley & Sons, Inc 01.07.2022
John Wiley and Sons Inc
Wiley
Subjects:
Age
Agonists
Brief Communication
Brief Communications
Confidence intervals
Patients
ISSN:2328-9503, 2328-9503
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Remyelination efficiency declines with advancing age in animal models, but this has been harder to demonstrate in people with multiple sclerosis. We show that bexarotene, a putatively remyelinating retinoid‐X receptor agonist, shortened the visual evoked potential latency in patients with chronic optic neuropathy aged under 42 years only (with the effect diminishing by 0.45 ms per year of age); and increased the magnetization transfer ratio of deep gray matter lesions in those under 43 years only. Addressing this age‐related decline in human remyelination capacity will be an important step in the development of remyelinating therapies that work across the lifespan.
Bibliography:This study was supported by the Cambridge NIHR Biomedical Centre and Clinical Research Facility and the UK MS Society.
Funding Information
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2328-9503
2328-9503
DOI:10.1002/acn3.51595